T1	Participants 104 165	progressive, metastatic, castration-resistant prostate cancer
T2	Participants 268 323	metastatic castration-resistant prostate cancer (mCRPC)
T3	Participants 346 407	Men with progressive mCRPC after docetaxel-based chemotherapy
T4	Participants 712 747	873 patients were randomly assigned
